Results 241 to 250 of about 4,347,639 (355)
857 Development of an mRNA cancer vaccine platform enabling flexible antigen exchange and dendritic cell selected delivery to overcome immune tolerance [PDF]
Sojin Lee, So-Young Kim, Helen Cho
openalex +1 more source
Plant‐derived extracellular vesicles offer numerous advantages and are regarded as highly promising candidates in the field of biomedicine. Abstract Extracellular vesicles (EVs) are double‐membrane vesicular structures that can be secreted by nearly all living cells.
Zilin Li +6 more
wiley +1 more source
Editorial: Advances in therapeutic cancer vaccines-mechanisms and development. [PDF]
George MM +4 more
europepmc +1 more source
862 An integrated preclinical platform utilizing HLA-humanized mouse models for comprehensive evaluation of mRNA cancer vaccines [PDF]
Jialu Fan +5 more
openalex +1 more source
Engineered yeast microreactors that produce H2O2 within tumors enable selective cancer cell killing while releasing immunostimulatory components, effectively suppressing local tumor growth and activating systemic antitumor immunity, with further efficacy enhanced by anti‐PD‐1 therapy and transarterial embolization.
Wenqian He +9 more
wiley +1 more source
Therapeutic cancer vaccines: navigating clinical translation and multimodal synergy. [PDF]
Chu TH, Huynh TL, Phuong LT.
europepmc +1 more source
1083 Induction of anti-cancer immunity by immunopeptidome-guided personalized peptide vaccines in advanced solid tumor patients [PDF]
Patrick Zimmermann +10 more
openalex +1 more source
Abstract Development of therapeutic bispecific antibodies (BsAbs) poses significant manufacturability challenges associated with correct chain pairing and an increased diversity of impurities. Here we address this with a product quality assessment during cell line development (CLD), forgoing the need for genetic characterization during cell line ...
Molly Robinson +7 more
wiley +1 more source
Cancer Vaccines: Mobilizing Immunity for Targeted Cancer Therapy. [PDF]
Yilmaz V.
europepmc +1 more source

